{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:56:50Z","timestamp":1781218610730,"version":"3.54.1"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKi) have expanded treatment options for rheumatoid arthritis (RA) by providing rapid and effective oral therapy. However, their optimal use has become increasingly complex after the emergence of safety concerns involving serious infections, herpes zoster (HZ), major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and malignancy. This issue is particularly relevant in Japan, where the RA population is older and has a higher prevalence of comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the risk-optimized use of JAKi for RA based on Japanese evidence, with particular emphasis on older patients, comorbidity-rich populations, and practical real-world treatment decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence acquisition<\/jats:title>\n                    <jats:p>We conducted a literature search of PubMed\/MEDLINE and Ichushi-Web to identify Japan-specific studies on JAKi in RA. Randomized trials, long-term extension studies, registry analyses, database studies, postmarketing surveillance reports, and observational studies were reviewed. Because of heterogeneity in design, patient background, and outcome definitions, the evidence was synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>Japanese evidence indicates that older age is an important but insufficient determinant of JAKi safety. Across studies, treatment outcomes were more strongly influenced by comorbidities, glucocorticoid exposure, laboratory abnormalities, and other patient-related risk factors. HZ emerged as the most consistent safety signal, supporting the importance of vaccination and early monitoring. By contrast, the risk of hospitalized infection was not consistently higher with JAKi than with biologic disease-modifying antirheumatic drugs in older patients, and Japanese evidence on MACE, VTE, and malignancy remained limited or inconsistent. Real-world studies also supported individualized dose optimization, whereas current data did not support routine within-class selection based primarily on JAK selectivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current Japanese evidence supports a risk-optimized approach to the use of JAKi in RA. Age alone should not determine treatment decisions. Instead, rheumatologists should individualize JAKi selection, dosing, and monitoring according to comorbidity profile, infection and vascular risk, malignancy background, and therapeutic priorities, particularly in increasingly older and multimorbid patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1842268","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:10:23Z","timestamp":1781215823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Japanese evidence on Janus kinase inhibitors for rheumatoid arthritis: a narrative review of risk-optimized use"],"prefix":"10.3389","volume":"17","author":[{"given":"Haruki","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Collagen Disease, Fukushima Red Cross Hospital","place":["Fukushima, Japan"]},{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Collagen Disease, Fukushima Red Cross Hospital","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nibu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Collagen Disease, Fukushima Red Cross Hospital","place":["Fukushima, Japan"]},{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]},{"name":"Department of Rheumatology, Ohta-Nishinouchi Hospital","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]},{"name":"Department of Rheumatology, Ohta-Nishinouchi Hospital","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sumichika","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]},{"name":"Department of Rheumatology, Ohta-Nishinouchi Hospital","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shimojima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine","place":["Fukushima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of jak inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B2","unstructured":"Appropriate use information for elderly patients"},{"key":"B3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/mr\/roab021","article-title":"Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: subpopulation analyses of 24-Week data of a global phase 3 study (finch 3)","volume":"32","author":"Atsumi","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","article-title":"Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with jak inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries","volume":"77","author":"Aymon","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of jakinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/ard-2024-225759","article-title":"Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years","volume":"83","author":"Burmester","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B7","unstructured":"Annual Report on the Ageing Society\n          \n          \n          2025"},{"key":"B8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib Versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from oral surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib Versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select phase iii clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib Versus tnf inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled oral surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s10067-020-05015-5","article-title":"Drug retention of secondary biologics or jak inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the answer cohort study","volume":"39","author":"Ebina","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","article-title":"Factors affecting drug retention of janus kinase inhibitors in patients with rheumatoid arthritis: the answer cohort study","volume":"12","author":"Ebina","year":"2022","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e003160","DOI":"10.1136\/rmdopen-2023-003160","article-title":"Drug retention of biologics and janus kinase inhibitors in patients with rheumatoid arthritis: the answer cohort study","volume":"9","author":"Ebina","year":"2023","journal-title":"RMD Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-023-03251-z","article-title":"Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-Year data from the kurama cohort","volume":"26","author":"Fujii","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B16","article-title":"24-Week, post-marketing surveillance analysis of upadacitinib in Japanese patients with rheumatoid arthritis: the 2024 interim report","volume":"76","author":"Fujii","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"Epub 20250911","DOI":"10.3390\/jcm14186409","article-title":"Pathogenic role of cytokines in rheumatoid arthritis","volume":"14","author":"Fujimoto","year":"2025","journal-title":"J. Clin. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-022-02883-x","article-title":"Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020","volume":"24","author":"Fukuda","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"B19","article-title":"Interview form for jyseleca tablets 200 Mg\/100 Mg.8th","author":"Gilead Sciences","year":"2026","journal-title":"Gilead Sci. K.K."},{"key":"B20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/mr\/road031","article-title":"Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological\/targeted synthetic disease-modifying antirheumatic drugs: evaluation of data from a Japanese claims database","volume":"34","author":"Harigai","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"Update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis: secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","article-title":"Real-world comparative study of the efficacy of janus kinase inhibitors in patients with rheumatoid arthritis: the answer cohort study","volume":"63","author":"Hayashi","year":"2024","journal-title":"Rheumatol. Oxf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to jak inhibitors Versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/rheumatology\/keae081","article-title":"Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the answer cohort study","volume":"64","author":"Jinno","year":"2025","journal-title":"Rheumatol. Oxf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (Select-Sunrise): a placebo-controlled phase iib\/iii study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatol. Oxf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (Select-Sunrise)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14397595.2020.1794103","article-title":"Efficacy and safety of peficitinib in rheumatoid arthritis","volume":"30","author":"Kaneko","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/mr\/roac046","article-title":"A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan","volume":"33","author":"Kaneko","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"Kato","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"Epub 20240730","DOI":"10.3390\/ijms25158327","article-title":"Jak inhibitors in rheumatoid arthritis: immunomodulatory properties and clinical efficacy","volume":"25","author":"Kielbowski","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10165-011-0518-4","article-title":"Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: tsurumai biologics communication registry (tbcr) study","volume":"22","author":"Kojima","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40744-023-00603-8","article-title":"Generation-dependent retention rates and reasons for discontinuation of molecular targeted therapies in patients with rheumatoid arthritis: from first registry","volume":"10","author":"Kubo","year":"","journal-title":"Rheumatol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e003029","DOI":"10.1136\/rmdopen-2023-003029","article-title":"Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (xanadu study): an open-label randomised study","volume":"9","author":"Kubo","year":"","journal-title":"RMD Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/mr\/roaf017","article-title":"Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: final analysis of an all-case postmarketing surveillance study","volume":"35","author":"Kuwana","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of tnf-inhibitors, abatacept, Il6-Inhibitors and jak-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'Jak-Pot' collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.23736\/S0026-4806.24.09409-6","article-title":"Multicenter observational study on the efficacy of selective janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis","volume":"115","author":"Lo","year":"2024","journal-title":"Minerva Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s41927-024-00446-y","article-title":"Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study","volume":"8","author":"Maeyama","year":"2024","journal-title":"BMC Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/ard.2006.063834","article-title":"Disease activity score 28 (Das28) using C-Reactive protein underestimates disease activity and overestimates eular response criteria compared with Das28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan","volume":"66","author":"Matsui","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/mr\/roae006","article-title":"Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: data from the ninja study","volume":"34","author":"Matsui","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e70363","DOI":"10.1111\/1756-185x.70363","article-title":"Incidence and risk of malignancy in Japanese patients with rheumatoid arthritis in the national database of rheumatic diseases in Japan (ninja database)","volume":"28","author":"Matsui","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40801-024-00423-4","article-title":"Treatment patterns of biologic disease-modifying antirheumatic drugs and janus kinase inhibitors in patients with rheumatoid arthritis in Japan: a claims-based cohort study","volume":"11","author":"Miyashiro","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e004987","DOI":"10.1136\/rmdopen-2024-004987","article-title":"Switching to biological dmards Versus cycling among jak inhibitors in patients with rheumatoid arthritis and with inadequate response to jak inhibitors: from first registry","volume":"11","author":"Miyazaki","year":"","journal-title":"RMD Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/rheumatology\/keae334","article-title":"Comparison of Anti-Il-6 receptor and jak inhibitors in patients with rheumatoid arthritis from the real-world practice first registry","volume":"64","author":"Miyazaki","year":"","journal-title":"Rheumatol. Oxf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the jak and tnf inhibitors in rheumatoid arthritis: real world data from the Hong Kong biologics registry","volume":"63","author":"Mok","year":"2024","journal-title":"Rheumatol. Oxf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1007\/s10067-019-04721-z","article-title":"Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study","volume":"38","author":"Mori","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","article-title":"Risk of venous thromboembolism associated with janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review","volume":"40","author":"Mori","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/mr\/roac029","article-title":"Impact of janus kinase inhibitors on antibody response to 13-Valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"33","author":"Mori","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"B48","first-page":"10","article-title":"Varied risk of developing Herpes zoster in rheumatoid arthritis patients treated with molecular targeting therapy: a single-center study","volume":"53","author":"Muramatsu","year":"2023","journal-title":"Kitasato Med. J."},{"key":"B49","volume-title":"Orthopaedics\/Rheumatology - Musculoskeletal and Cutaneous Surgery - Laboratories","year":"2026"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the national database of health insurance claims and specific health checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/mr\/roae064","article-title":"Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study","volume":"35","author":"Okamoto","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"Epub 20240704","DOI":"10.3390\/jcm13133929","article-title":"Influence of safety warnings on the prescribing attitude of jak inhibitors for rheumatoid arthritis in Italy","volume":"13","author":"Paroli","year":"2024","journal-title":"J. Clin. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/medicina60121982","article-title":"Effectiveness and predictors of long-term treatment response to tofacitinib in rheumatoid arthritis cohort: general analysis and focus on high-cardiovascular-risk Subgroup-a multicenter study","volume":"60","author":"Priora","year":"2024","journal-title":"Med. Kaunas."},{"key":"B54","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1586\/eci.12.35","article-title":"Current treatments of rheumatoid arthritis: from the 'ninja' registry","volume":"8","author":"Saeki","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e0306714","DOI":"10.1371\/journal.pone.0306714","article-title":"Real-world comparative study of drug retention of janus kinase inhibitors in patients with rheumatoid arthritis","volume":"19","author":"Saito","year":"2024","journal-title":"PLoS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-022-02807-9","article-title":"Unincreased risk of hospitalized infection under targeted therapies Versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study","volume":"24","author":"Sakai","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"Epub 20240617","DOI":"10.1136\/rmdopen-2023-003885","article-title":"Increased risk of cardiovascular events under the treatments with janus kinase inhibitors Versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database","volume":"10","author":"Sakai","year":"2024","journal-title":"RMD Open"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1565909","DOI":"10.3389\/fphar.2025.1565909","article-title":"Frailty and cardiovascular safety of jak inhibitors Versus tnf inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles","volume":"16","author":"Silvagni","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/acr.25282","article-title":"Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted-synthetic disease-modifying antirheumatic drugs","volume":"76","author":"Singh","year":"2024","journal-title":"Arthritis Care Res. Hob."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.01.023","article-title":"Eular recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update","author":"Smolen","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e70232","DOI":"10.1111\/1756-185X.70232","article-title":"Targeted therapies for rheumatoid arthritis in super-elderly society: insights from first registry, Japan","volume":"28","author":"Sonomoto","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40744-025-00762-w","article-title":"Real-world safety and efficacy of targeted therapies in rheumatoid arthritis: a 5-Year, 5130-Case Follow-up from first registry","volume":"12","author":"Sonomoto","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e006503","DOI":"10.1136\/rmdopen-2025-006503","article-title":"Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-Year observational study from first registry","volume":"12","author":"Sonomoto","year":"2026","journal-title":"RMD Open"},{"key":"B64","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/mr\/roae026","article-title":"Systematic review for the treatment of older rheumatoid arthritis patients informing the 2024 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis","volume":"34","author":"Sugihara","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/tiu2h4","article-title":"Impact of concomitant methotrexate on jak inhibitors in rheumatoid arthritis-associated interstitial lung disease: a retrospective single-centre study from the Keio-Ra cohort","author":"Suzuki","year":"2026","journal-title":"Clin. Exp. Rheumatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/mr\/roab030","article-title":"Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: subpopulation analyses of 24-Week data of a global phase 3 study (finch 1)","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6154-25","DOI":"10.2169\/internalmedicine.6154-25","article-title":"Preventive effectiveness of recombinant zoster vaccine in rheumatoid arthritis patients treated with janus kinase inhibitors","author":"Tabata","year":"2025","journal-title":"Intern Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/mr\/roac133","article-title":"Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: a population-based retrospective cohort study","volume":"33","author":"Takabayashi","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"21907","DOI":"10.1038\/s41598-020-78925-8","article-title":"Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry","volume":"10","author":"Takahashi","year":"2020","journal-title":"Sci. Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.2169\/internalmedicine.3288-23","article-title":"A preliminary survey of rheumatologists on the management of late-onset rheumatoid arthritis in Japan","volume":"63","author":"Takanashi","year":"2024","journal-title":"Intern. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2025.2590230","article-title":"Drug retention rate of janus kinase inhibitors in patients with rheumatoid arthritis: the Keio-Ra cohort study","author":"Takanashi","year":"2025","journal-title":"Immunol. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral janus kinase inhibitor peficitinib (Asp015k) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-Week, randomised, double-blind, placebo-controlled phase iib study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/14397595.2018.1553489","article-title":"Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post hoc analysis of clinical trial data","volume":"29","author":"Takeuchi","year":"","journal-title":"Mod. Rheumatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (Asp015k) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii randomised, double-blind, placebo-controlled trial (Raj4) in Japan","volume":"78","author":"Takeuchi","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40744-021-00280-5","article-title":"Safety and effectiveness of peficitinib (Asp015k) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"8","author":"Takeuchi","year":"","journal-title":"Rheumatol. Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14397595.2020.1836789","article-title":"A pooled safety analysis of peficitinib (Asp015k) in Asian patients with rheumatoid arthritis treated over a median of 2 years","volume":"31","author":"Takeuchi","year":"","journal-title":"Mod. Rheumatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14397595.2020.1859675","article-title":"Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: subgroup analyses of a global phase 3 study (finch 2)","volume":"32","author":"Takeuchi","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/mr\/roaf007","article-title":"Real-world treatment persistence in Csdmard-Ir and Bdmard-Ir patients with rheumatoid arthritis in Japan: a large claims database study","volume":"35","author":"Takeuchi","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase Ii study of tofacitinib (Cp-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res. Hob."},{"key":"B80","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-Week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-Week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J. Rheumatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-Week, randomized, single-blind, extension study","volume":"28","author":"Tanaka","year":"","journal-title":"Mod. Rheumatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"","journal-title":"Mod. Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (Asp015k) in patients with rheumatoid arthritis and an inadequate response to conventional dmards: a randomised, double-blind, placebo-controlled phase iii trial (Raj3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/mr\/roac084","article-title":"Safety and efficacy of filgotinib for Japanese patients with Ra and inadequate response to mtx: finch 1 52-Week results and finch 4 48-Week results","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/mr\/roae099","article-title":"Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: week 156 interim results in finch 4","volume":"35","author":"Tanaka","year":"2025","journal-title":"Mod. Rheumatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41927-026-00621-3","article-title":"Real-world effectiveness and safety of upadacitinib in Japanese patients with rheumatoid arthritis: impact of age, renal function, and low-dose therapy","volume":"10","author":"Tanno","year":"2026","journal-title":"BMC Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatol. Oxf."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.3390\/jcm12144585","article-title":"Drug retention rates and the safety of janus kinase inhibitors in elderly patients with rheumatoid arthritis","volume":"12","author":"Temmoku","year":"","journal-title":"J. Clin. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.3390\/jcm12144827","article-title":"Drug retention rates of janus kinase inhibitors in rheumatoid arthritis patients with therapy-induced lymphopenia","volume":"12","author":"Temmoku","year":"","journal-title":"J. Clin. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"Jak selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","article-title":"Comparison of risks of cancer, infection, and maces associated with jak inhibitor and tnf inhibitor treatment: a multicentre cohort study","volume":"62","author":"Uchida","year":"2023","journal-title":"Rheumatol. Oxf."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e70572","DOI":"10.1111\/1756-185x.70572","article-title":"Risk factors for major adverse cardiovascular events, malignancies, and serious infections with tofacitinib in rheumatoid arthritis: post hoc analysis of a 3-Year J-Post-Marketing surveillance","volume":"29","author":"Yamaoka","year":"2026","journal-title":"Int. J. Rheum. Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.3390\/jcm13103000","article-title":"Incidence rates of infections in rheumatoid arthritis patients treated with janus kinase or Interleukin-6 inhibitors: results of a retrospective, multicenter cohort study","volume":"13","author":"Yoshida","year":"2024","journal-title":"J. Clin. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1093\/rheumatology\/keaf050","article-title":"Efficacy and safety of first-line targeted synthetic dmards in rheumatoid arthritis patients with chronic kidney disease","volume":"64","author":"Yoshimura","year":"2025","journal-title":"Rheumatol. Oxf."},{"key":"B100","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:10:24Z","timestamp":1781215824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":100,"alternative-id":["10.3389\/fphar.2026.1842268"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1842268","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1842268"}}